Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use ...

In a small trial, Novo Nordisk's diabetes drug Ozempic showed promise in reducing alcohol consumption and cravings in ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...